<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02405260</url>
  </required_header>
  <id_info>
    <org_study_id>TTP399-202</org_study_id>
    <nct_id>NCT02405260</nct_id>
  </id_info>
  <brief_title>Add Glucokinase Activator to Target A1c</brief_title>
  <acronym>AGATA</acronym>
  <official_title>A Multi-Center, Adaptive Phase 2, Randomized, Double-Blind, Placebo- and Active-Controlled (Sitagliptin), Parallel Group Study to Evaluate the Safety and Efficacy of TTP399 Following 6 Months Administration in Subjects With Type 2 Diabetes Mellitus on A Stable Dose of Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>vTv Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>vTv Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a multi-center, adaptive, randomized, double-blind, placebo- and active-
      controlled, parallel group, Phase 2 study in subjects with T2DM to evaluate the effect of
      TTP399 on HbA1c following administration for 6 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c (Glycosylated haemoglobin)</measure>
    <time_frame>Day 1 to Day 168</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c &lt; 7% at 6 months</measure>
    <time_frame>Day 1 to Day 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c &lt; 6.5% at 6 months</measure>
    <time_frame>Day 1 to Day 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucose Levels</measure>
    <time_frame>Day 1 to Day 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid Levels</measure>
    <time_frame>Day 1 to Day 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Levels</measure>
    <time_frame>Day 1 to Day 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate Levels</measure>
    <time_frame>Day 1 to Day 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide Levels</measure>
    <time_frame>Day 1 to Day 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon Levels</measure>
    <time_frame>Day 1 to Day 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon-like Peptide-1 Levels</measure>
    <time_frame>Day 1 to Day 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight</measure>
    <time_frame>Day 1 to Day 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Day 1 to Day 182</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Day 1 to Day 182</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram Parameters</measure>
    <time_frame>Day 1 to Day 182</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology</measure>
    <time_frame>Day 1 to Day 182</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Chemistry</measure>
    <time_frame>Day 1 to Day 182</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinalysis</measure>
    <time_frame>Day 1 to Day 182</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>Day 1 to Day 182</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">190</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>TTP399 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTP399 once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TTP399 800 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTP399 once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sitagliptin once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTP399 400 mg</intervention_name>
    <description>once daily</description>
    <arm_group_label>TTP399 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTP399 800 mg</intervention_name>
    <description>once daily</description>
    <arm_group_label>TTP399 800 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin 100 mg</intervention_name>
    <description>once daily</description>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A historical diagnosis of Type 2 Diabetes in accordance with the American Diabetes
             Association (ADA) guidelines, with diagnosis at least 6 months prior to Screening.

          -  On a stable (for the last 3 months prior to screening) regimen of metformin
             monotherapy equivalent of at least 1000 mg once daily.

          -  Males, females of childbearing potential (must have a negative pregnancy test and be
             willing to comply with protocol contraception), and females of non-childbearing
             potential.

          -  Age 18 to 75 years, inclusive, at the time of screening.

          -  HbA1c ≥7.0% and ≤9.5%.

          -  Generally stable health without active infection or history of major surgery or
             significant injuries within the last year.

        Exclusion Criteria:

          -  Diagnosis of Type 1 diabetes mellitus, maturity-onset diabetes of the young,
             insulin-requiring Type 2 Diabetes, other unusual or rare forms of diabetes mellitus,
             or history of diabetic ketoacidosis.

          -  Clinically significant abnormal lab values including eGFR &lt;50ml/min/1.73m2, ALT,
             bilirubin or AST &gt;1.5 X ULN, hypokalemia or other clinically significant electrolyte
             abnormality.

          -  History of myocardial infarction, unstable angina, coronary revascularization, stroke,
             or transient ischemic attack within 2 years of screening.

          -  Presence of symptomatic congestive heart failure.

          -  History of cardiac arrhythmias requiring treatment or prophylaxis with drugs or
             devices during the last 2 years or any history of atrial fibrillation or flutter
             beyond a single short-term episode (e.g., lasting 1-2 days).

          -  History or presence of a 2nd degree or greater atrioventricular block in the absence
             of a pacemaker.

          -  A 12-lead ECG, from screening or baseline demonstrating QTcF interval &gt;450 msec for
             males or &gt;47 msec for females.

          -  A family or personal history of long QT syndrome.

          -  History of pancreatitis.

          -  Persistent, uncontrolled hypertension.

          -  Presence of chronic active hepatitis (hepatitis B, hepatitis C, nonalcoholic
             steatohepatitis [NASH]) and/or known liver cirrhosis.

          -  Participation in any formal weight loss program, or fluctuation of &gt; 5% in body
             weight, or having received medications approved for weight loss within 3 months prior
             to screening.

          -  A positive pre-study drug screen.

          -  Participation in a clinical trial and receipt of an investigational product within 30
             days.

          -  Have a history of drug abuse within 2 years of screening or a positive pre-screen drug
             screen.

          -  Have a history of hypoglycemic episode requiring glucose, glucagon, or orange juice
             administered by someone other than the patient within 6 months prior to screening.

          -  A history of excessive alcohol consumption within the last 2 years prior to screening

          -  Mental or legal incapacitation.

          -  Blood donation of approximately 1 pint (500 mL) within 8 weeks.

          -  History of MEN-2 or family history of medullary thyroid cancer.

          -  History of cancer, other than non-melanoma skin cancer, that required therapy in the 5
             years prior study start.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmen Valcarce, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>vTv Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tuscon</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Hills</city>
        <state>California</state>
        <zip>91307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <zip>60031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moncks Corner</city>
        <state>South Carolina</state>
        <zip>29461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Schertz</city>
        <state>Texas</state>
        <zip>78154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richland</city>
        <state>Washington</state>
        <zip>99352</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2015</study_first_submitted>
  <study_first_submitted_qc>March 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2015</study_first_posted>
  <disposition_first_submitted>February 9, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>February 9, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 10, 2017</disposition_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

